{"id":"W2560717039","doi":"10.1056/nejmoa1612674","title":"Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3329,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Osimertinib; T790M; Pemetrexed; Lung cancer; Medicine; Epidermal growth factor receptor; Oncology; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Cancer research; Chemotherapy; Cancer; Receptor; Erlotinib; Gefitinib; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}